16.54
2.71%
-0.46
After Hours:
13.75
-2.79
-16.87%
Igm Biosciences Inc stock is traded at $16.54, with a volume of 744.89K.
It is down -2.71% in the last 24 hours and up +62.32% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$17.00
Open:
$16.7
24h Volume:
744.89K
Relative Volume:
2.27
Market Cap:
$981.72M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-3.1385
EPS:
-5.27
Net Cash Flow:
$-176.15M
1W Performance:
+3.44%
1M Performance:
+62.32%
6M Performance:
+71.40%
1Y Performance:
+98.08%
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-09-22 | Resumed | Jefferies | Buy |
Oct-17-22 | Initiated | JP Morgan | Neutral |
Aug-29-22 | Initiated | BofA Securities | Buy |
Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
Aug-26-21 | Initiated | Morgan Stanley | Overweight |
Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
Jul-17-20 | Initiated | Robert W. Baird | Outperform |
Jul-01-20 | Initiated | H.C. Wainwright | Buy |
May-28-20 | Initiated | SunTrust | Buy |
Apr-22-20 | Initiated | Wedbush | Outperform |
Oct-14-19 | Initiated | Guggenheim | Buy |
Oct-14-19 | Initiated | Jefferies | Buy |
Oct-14-19 | Initiated | Piper Jaffray | Overweight |
Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust By Investing.com - Investing.com Canada
IGM Biosciences shifts focus to autoimmune therapies - Investing.com
IGM Biosciences to minimize spending on oncology candidates, appoints new CEO - Seeking Alpha
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity - The Bakersfield Californian
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity - GlobeNewswire
IGM Biosciences' SWOT analysis: promising pipeline drives stock potential - Investing.com
Rhumbline Advisers Purchases 2,635 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
While shareholders of IGM Biosciences (NASDAQ:IGMS) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 6.8% - Defense World
Bank of New York Mellon Corp Has $371,000 Stock Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 2.7% - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Shares Up 2.7% - Defense World
IGM BIOSCIENCES INC Revenue Breakdown – TRADEGATE:1K0 - TradingView
Learn to Evaluate (IGMS) using the Charts - Stock Traders Daily
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
IGM Financial (TSE:IGM) Hits New 1-Year High at $40.00 - MarketBeat
Ipsy names CEO - Retail Dive
Misbah Tahir Sells 1,487 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock - Defense World
Ipsy Appoints Galen C. Smith As CEO - Beauty Packaging
Fred Schwarzer Sells 3,946 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock - Defense World
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
IGG (OTCMKTS:IGGGF) Shares Up 46.9% - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading Down 4.1% on Insider Selling - Defense World
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? - MSN
Imagion Biosystems Issues New Equity Securities - TipRanks
Ick (2024) - Screen Rant
IGM Biosciences (NASDAQ:IGMS) Trading 5.1% Higher - Defense World
IGM Biosciences: Waiting For Godot (NASDAQ:IGMS) - Seeking Alpha
Russell 2000 Outpaces S&P 500 As Small Caps Anticipate Fed's Interest Rate Move - Benzinga
IGM Biosciences (NASDAQ:IGMS) Shares Down 4.1% After Insider Selling - MarketBeat
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? - Yahoo Finance
What was IGM Biosciences Inc (IGMS)’s performance in the last session? - US Post News
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Bought by Quest Partners LLC - Defense World
IGM Biosciences chief scientific officer sells $17k in stock By Investing.com - Investing.com South Africa
IGM Biosciences CFO sells over $17k in company stock By Investing.com - Investing.com Canada
IGM Biosciences CFO sells over $17k in company stock - Investing.com
IGM Biosciences CEO sells shares worth over $45,000 By Investing.com - Investing.com Canada
IGM Biosciences executive sells over $17k in company stock By Investing.com - Investing.com Australia
IGM Biosciences chief scientific officer sells $17k in stock - Investing.com
IGM Biosciences CEO sells shares worth over $45,000 - Investing.com India
IGM Biosciences chief scientific officer sells $17k in stock By Investing.com - Investing.com UK
IGM Biosciences executive sells over $17k in company stock - Investing.com
IGM Biosciences (NASDAQ:IGMS) Hits New 1-Year High at $18.34 - MarketBeat
IGM Biosciences Inc (IGMS) may enjoy gains as insiders got busy in the recent days - Knox Daily
IGM Biosciences Inc (IGMS) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
IGL Share Price Target 2025: UBS upgrades rating to BUYKnow why - ET Now
IGM Biosciences CEO sells shares worth over $45,000 - Investing.com
Bispecific Antibody Clinical Trials 2024: FDA Approvals, - openPR
IGM Biosciences (NASDAQ:IGMS) Stock Price Up 5.1% - MarketBeat
TD Asset Management Inc Grows Stock Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):